简报:依沃西单抗联合依托泊苷加卡铂一线治疗广泛期小细胞肺癌:1b期临床试验结果
这项1b期临床试验评估依沃西单抗联合依托泊苷和卡铂一线治疗广泛期小细胞肺癌的安全性和初步疗效,35例患者入组,确认客观缓解率为80%,疾病控制率为91.4%,≥3级治疗相关不良事件发生率为60%,结论为该方案耐受良好并显示出有前景的抗肿瘤活性。
要点
- 35例广泛期小细胞肺癌患者接受依沃西单抗联合依托泊苷和卡铂一线治疗,确认ORR为80%,DCR为91.4%。
- ≥3级治疗相关不良事件发生率为60%,最常见为中性粒细胞计数降低(22.9%)、白细胞计数降低(14.3%)和贫血(14.3%)。
- 导致死亡的治疗相关不良事件报告于2例患者(5.7%)。
核心结论
- 依沃西单抗联合依托泊苷和卡铂在广泛期小细胞肺癌中耐受良好,并显示出有前景的抗肿瘤活性。
研究设计与样本
- 1b期临床试验,评估依沃西单抗联合依托泊苷和卡铂一线治疗广泛期小细胞肺癌的安全性和耐受性并探索初步疗效。
- 符合条件的患者接受静脉依沃西单抗3 mg/kg、10 mg/kg或20 mg/kg每3周一次联合依托泊苷和卡铂最多4个周期,后续依沃西单抗维持治疗。
- 主要终点为安全性和客观缓解率(ORR)。
- 2021年4月23日至2021年12月2日期间共入组35例患者。
主要发现
- 数据截止2023年10月25日,中位随访时间为13.3个月(范围:0.3-28.5)。
- 全部患者的确认ORR为80%,疾病控制率为91.4%。
- 3 mg/kg、10 mg/kg和20 mg/kg剂量组的ORR分别为66.7%、90.9%和76.2%。
- 21例患者(60%)观察到≥3级治疗相关不良事件(TRAEs),最常见的毒性为中性粒细胞计数降低(n=8,22.9%)、白细胞计数降低(n=5,14.3%)和贫血(n=5,14.3%)。
- 3、10和20 mg/kg组≥3级TRAEs发生率分别为66.7%、54.5%和61.9%,2例患者(5.7%)报告导致死亡的TRAEs,14例患者(40.0%)发生免疫相关不良事件,多为1级或2级。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Ivonescimab is a humanized IgG1 bispecific anti-programmed cell death protein 1/vascular endothelial growth factor antibody. This study aimed to evaluate the safety and tolerance of ivonescimab combined with etoposide and carboplatin as first-line treatment in patients with extensive-stage SCLC and to explore the primary efficacy of this regimen. METHODS: Eligible patients received intravenous ivonescimab 3 mg/kg, 10 mg/kg, or 20 mg/kg every 3 weeks combined with etoposide and carboplatin for up to four cycles, followed by ivonescimab as maintenance. The primary end points were safety and objective response rate (ORR). RESULTS: Between April 23, 2021, and December 2, 2021, 35 patients were enrolled. At data cutoff (October 25, 2023), the median follow-up was 13.3 (range: 0.3-28.5) months. For all patients, the confirmed ORR and disease control rate were 80% and 91.4%, respectively. The ORR was 66.7%, 90.9%, and 76.2% at the dose of 3 mg/kg, 10 mg/kg, and 20 mg/kg, respectively. Grade more than or equal to 3 treatment-related adverse events (TRAEs) were observed in 21 patients (60%), and the most frequent toxicities were decreased neutrophil count (n = 8, 22.9%), decreased white blood cell count (n = 5, 14.3%), and anemia (n = 5, 14.3%). Grade more than or equal to 3 TRAEs occurred in 66.7%, 54.5%, and 61.9% of patients in 3, 10, and 20 mg/kg groups, respectively. TRAEs leading to death were reported in two patients (5.7%). Immune-related adverse events, most of them grade 1 or 2, occurred in 14 patients (40.0%). CONCLUSIONS: Ivonescimab in combination with etoposide and carboplatin was well tolerated and found to have promising antitumor activity in extensive-stage SCLC.
引用
- Chen Z, Wu L, Wang Q, et al. Brief Report: Ivonescimab Combined With Etoposide Plus Carboplatin as First-Line Treatment for Extensive-Stage SCLC: Results of a Phase 1b Clinical Trial. J Thorac Oncol. 2024. PMID: 39490738. doi:10.1016/j.jtho.2024.10.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。